Minimally Invasive Autologous Bone Marrow Concentrate Stem Cells in the Treatment of the Chronically Injured Achilles Tendon: A Case Report

By: McKenna, R. W., DO & Riordan, N. H., Ph.D

Abstract

INTRODUCTION: Achilles tendinopathy is a painful, degenerative condition that limits mobility in daily activities and physical exertion. When conservative treatment fails, surgery is usually considered. There is a growing development of less invasive treatments to correct affected tendons.

BACKGROUND: Autologous Bone Marrow Concentrate (BMAC) contains concentrated growth factors, CD34+ stem cells and mesenchymal stem cells, which have angiogenic, trophic, and anti-inflammatory effects on tissues and may be useful in the regeneration of tendon tissue.

AIM - CASE REPORT: We present a case of severe chronic MRI confirmed Achilles tendinopathy in a 56-year-old female treated with ultrasound guided injection of autologous Bone Marrow Aspirate Concentrate (BMAC).

MATERIALS AND METHODS: In an office setting, bone marrow was aspirated from the metaphyseal area of the medial tibia and concentrated with a closed system. The resulting BMAC was injected intralesionally into the affected tendinotic mid substance area under ultrasound guidance.

RESULTS: Eight weeks after intervention, the patient reported remarkably less pain and had resumed normal daily activities and intense exercise. Her ankle showed markedly less tenderness and progression toward homogeneity on the 10-week MRI with T1 relative strength intensity (RSI) improvement from 307.8 to 182.5 units at the most affected area of the lesion.

NOTE: Since the publication of this article by CellR4 on July 26, 2014, a 32-week post-treatment MRI was performed using the same scanner as the pre-treatment and 10-week post-treatment MRIs. The 32-week MRI images showed near complete healing of the treated tendon. See the ’In Press: Editor,’ section later in this report.

DISCUSSION: To our knowledge this is the first report of the successful treatment of Achilles tendinopathy using autologous BMAC.

CONCLUSIONS: This case report of the non-surgical, minimally invasive use of BMAC to successfully treat chronic Achilles tendinopathy should lead to further controlled studies of this potential alternative to surgical intervention.

Background

The Achilles tendon is a richly vascularized tissue at the junction of the gastrocnemius and soleus muscles, bearing heavy loads during physical exertion. Achilles tendinopathy frequently affects those engaging in racquet sports, running and other recreational activities, and is thought to be caused by many intrinsic and extrinsic factors such as weight, age or training techniques. The main symptom of this complex, degenerative condition is pain during exercise, with swelling of the tendon during acute phases.
Treatment for Achilles tendinopathy is chiefly conservative, starting with immobilization and correction of training errors. Regimens of specific eccentric and concentric exercises can result in 82% of patients returning to normal activities in 12 weeks and 36% at 12 months, respectively 9, 10. Therapeutic ultrasound may reduce swelling during the acute phase in some cases, but has not been shown to be beneficial over placebo treatment11, 12, 13. Other conservative methods include extracorporeal shockwave therapy, splinting/bracing and low-level laser therapy. Only the eccentric loading exercises show the most efficacious symptomatic outcomes 14, 15 but without improvement in tendon structure 16.

Conservative treatments yield no improvement in 25 - 45% of patients and surgery must be considered 17. During the standard surgical procedure, the tendon is incised longitudinally to restore vascularity and is cleaned of degenerated nodules and fibrotic adhesions 18. If practiced with endoscopic incisions, pain decreases are seen in 6 months 19, 20, whereas with gastronecnius lengthening, improvements in tendon quality occur after one year, and return to sporting activity in two years 21.

A variety of injection-based therapies have emerged as less traumatic treatment options for tendinopathies 22. During prolotherapy, the injection of a hyperosmolar dextrose solution acts as an irritant to produce an inflammatory response 23, and has been shown to improve the condition in some cases 24, 25 with pain reduction at 28 months 26. Injection with corticosteroids can result in short term benefit, although adverse effects including tendon atrophy are reported in 82% of corticosteroid injection trials 27. Injection with Platelet Rich Plasma (PRP) has been shown to improve tendon healing 28, 29 and reduces healing time in anterior cruciate ligament reconstruction 30. However, PRP has not been shown to be effective for treating Achilles tendinopathy 31, 32, 33. Autologous blood injections have been used to treat affected tendons 34, 35, 36 and resulted in small improvements of Achilles tendinopathy after 12 weeks 37.

Injection with autologous bone marrow aspirate concentrate (BMAC) is a cell-based therapy for tendinopathies 38, 39. It has been shown to be beneficial for treatment and regeneration in different human pathologies 40, 41, 42 and in animal models 43, 44. Smith et al 45 showed enhanced healing of naturally occurring tendinopathies in an equine model by injecting cultured autologous mesenchymal stem cells suspended in bone marrow supernatant, reporting no adverse findings and enhanced normalization of biomechanical, morphological and compositional parameters.

To our knowledge, this report is the first clinical case of BMAC injection to treat Achilles tendinopathy.
Case Report

A 56-year-old female reported on first visit a painful “knot” in her left Achilles tendon. After ten years of symptoms, the pain limited her ability to participate in daily activities such as shopping, being up on her feet for longer than 30 minutes and wearing shoes other than sandals. She had been a very active tennis player and recreational athlete, but had been unable to fully participate in court sports for over a decade. She complained of point tenderness at the knot and described morning pain that would dissipate within one hour of waking, and pain upon exercise that would peak at the beginning and the end of her workouts.

On physical examination, the patient had a large, palpable knot in the midsubstance of the Achilles tendon, readily noticeable and acutely tender. She reported a VAS Pain Scale of 3 at rest, and significant pain and tenderness (VAS of 8) with any compression when relaxed, as well as tenderness to palpation with mobilization from either the medial or lateral side of the knot. She also reported great pain and a VAS of 9 on walking.

For radiographic diagnosis, she underwent an MRI scan of the midsubstance area of the Achilles tendon, including coronal and sagittal STIR, coronal, sagittal, and axial T1, as well as axial T2 images. The MRI showed severe hypertrophic changes with marked tendinopathy and a consistent intermediate T1 signal throughout the thick, echogenic area (Figure 1). The cross-sectional area of hypertrophic Achilles measured $2.272 \text{cm}^2$ at the largest point, extending from about a centimeter above the superior reflection over a distance of about 6-cm, and measured about 2-cm coronally and 1.5-cm from A to P. The relative signal intensity (RSI) was 307.839. Plain radiographs of the ankle and foot showed some pes planus deformity of the foot, but no significant osteoarthritic changes of the ankle.

At this point, the patient had been to multiple physicians and had followed ten years of standard conservative treatment with stretches and anti-inflammatories. She had refused multiple offers of invasive operative interventions that could not promise return to court sports. She had also declined corticosteroid shots secondary to her knowledge of the atrophic affect of steroids.

During detailed discussions, the patient was informed of her options of either the conservative therapy, which she had already tried and failed, or of the standard surgical procedure for Achilles tendinopathy, which she had been and still was unwilling to try. She was also presented with the possibility of attempting autologous BMAC therapy, to which she agreed with informed consent. She chose to have a non-operative intervention consisting of an in-office ultrasound guided injection of BMAC into the area of tendinosis.

Procedure

The proximal tibia was steriley prepped and draped. A 1% lidocaine with epinephrine solution was injected in a subperiosteal wheel to prevent pain at the insertion of the Bio-MAC® Bone Marrow Aspiration Catheter. (Biologic Therapies, Inc., Ocala, FL, USA).

A point was chosen for the insertion portal, just two finger-widths medial to the tibial tubercle and two fingers below the joint surface into the medial face, just at the metaphyseal area of the medial tibia. A 0.5-cm incision was made with a 15-blade scalpel to help avoid platelet activation at the time of catheter incision. The Bio-MAC aspiration catheter was inserted under power into the medial metaphyseal area and intramedullary area of the proximal tibia.

The inner trocar was removed and the plunger was inserted through the catheter to create a better draw zone and to decrease the turbidity and platelet activation at the time of the draw. The catheter and the syringe were coated with ACD-A prior to use, to avoid clotting and platelet activation and a
decrease in cell counts at the time of the aspiration. 60-cc of bone marrow were withdrawn through the catheter. The patient tolerated the aspiration well. The aspiration catheter was removed from the insertion portal and the incision closed with #3-0 nylon. For postoperative pain control, 3-cc of 1.5% plain Marcaine were injected.

The bone marrow aspirate was passed off the sterile field and concentrated using a Bio-SPIN™ Magellan System, a system optimized for centrifugal fractionation of peripheral blood and bone marrow in which the separation process is completely automated (Box 1). This yielded 5-cc of Bone Marrow Aspirate Concentrate (BMAC). Subsequently, these 5-cc of BMAC were introduced intralesionally into 4 locations through a 22-gauge needle, under ultrasound guidance in real time. This was done within the most tendinotic midsubstance area and into the slight periphery. The patient tolerated the procedure well.

The patient was discharged and returned for follow-up at six and eight weeks and was scheduled for a follow up MRI ten weeks post-procedure.

Results

Upon first follow-up six weeks postoperatively, the patient reported VAS score of 0 at rest, and 3 during walking, and 0 at rest and 2 while walking at the eight-week follow-up (Table 1). On physical examination, the knot was less than 50% the size that it was preoperatively. It had decreased grossly in its physical appearance and was relatively non-tender to palpation. The patient was able to toe-raise without tenderness. She reported wearing multiple types of shoes, and had been walking on uneven surfaces in heels over the last several weeks without pain or difficulties. At the eight-week mark, she was back to playing tennis without significant pain or problems, and was tolerating significant increases in her activity without pain or difficulty.

A second MRI was performed ten weeks post procedure, again including coronal and sagittal STIR, coronal, sagittal, and axial T1 and T2 images. At this stage, the thickened Achilles tendon measured about 1.75-cm coronally, 1.39-cm A to P, and 1.877-cm² cross-sectionally at the largest point (Figure 2). There was less signal hyperintensity on STIR and while some intermediate T1 signal remained, it was more normalized than on the previous MRI. The signal followed a reticular pattern, where more hypointense T1 signal was seen beneath and interposed between areas of slight T1 shortening, with a mosaic appearance in the posterior aspect of the tendon. The relative signal intensity (RSI) at follow-up was 182.471.

Discussion

To our knowledge, this is the first case report of the successful treatment for chronic Achilles tendinopathy using a single therapeutic intervention of BMAC. A 56-year-old patient was treated for chronic pain in the Achilles tendon preventing her from playing tennis and for which conservative treatment had failed. The patient reported resuming daily activities and physical exercise with minimal pain only eight weeks later, in contrast with the standard surgical procedure, where recovery time is at least six months. It should be noted that in ten years, no treatment that the patient had received provided this type of relief. Furthermore, traditional surgery, which can restore function to the tendon and relieve some of the pain with activity, does not restore homogeneity to the post surgical tendon.

The use of BMAC injection into the diseased or injured Achilles tendon was performed based on our experience using BMAC at the time of ACL reconstruction with Achilles tendon allografts. It is not uncommon to see MRI evidence of incorporation of Achilles tendon allografts as early as sixteen to twenty weeks in patients treated with BMAC at time of surgery. It has already been reported that the time to incorporation of ACL grafts has been reduced by almost 50% by the use of PRP. BMAC has
all the qualities of PRP from a growth factor concentration standpoint that has the significant advantage of containing the angiogenic and trophic effects of CD34+ cells and the angiogenic, anti-inflammatory, and trophic effects of mesenchymal stem cells.

In this case the medial proximal tibia was chosen for the aspiration site because the patient did not need to be repositioned for the intra-lesional injection. The procedure for bone marrow aspiration, concentration and injection was less than 60 minutes. Prior to the advent of bone marrow aspiration catheters such as the Bio-MAC, the only real option for bone marrow aspiration, concentration and injection into the lesion would have involved a trip to the operating room, and the use of a Jamshidi aspiration needle into the iliac crest under general anesthesia. In the experience of RWM the Bio-MAC can be used in the office setting in awake patients without the use of general anesthesia. It can be used to aspirate bone marrow from the medial proximal tibia, other long bones, and in some cases the iliac crest.

The goal of using autologous biologics is not to change the pathophysiologic process of healing in the human body. Instead, it is to avoid or shorten the inflammatory phase of healing and hasten the progression to remodeling and restoration of function of the treated tendon. The rationale for the use of BMAC injection into the torn or partially torn tendon is the same as for the use of BMAC into the allograft Achilles at the time of ACL reconstruction, the torn or partially torn rotator cuff, the diseased or tendinotic infrapatellar tendon, and the torn or partially torn common extensor tendon of the elbow. The treatment is to restore cellular volume and tissue viability to the injured or chronically injured acellular fibrotic tissue involved in the disease process that is acting to cause pain and limiting function. In this treatment example the chronically injured 10-year-old partially torn Achilles tendon treated with BMAC was able to begin the healing process within the first six weeks post procedure. Homogeneity was returning on MRI demonstrating a return of cellular volume and healthier tissue. Echogenicity was reduced demonstrating healthier, more viable tissue, and pain, which had limited function for over 10 years was relieved with a nonsurgical procedure.

The surgical approach would have involved immobilization and resulted in an adjacent soft tissue atrophy, postsurgical osteopenia of the bones of the foot and ankle and the need for significant physical therapy. In this case we were able to avoid the risks of surgical treatment and obtain healthier tissue, relieve pain and restore function in a truly minimally invasive fashion.

There is nothing currently documented that changes the echogenicity of a tendon towards a healing, normal appearing tendon, with homogeneity returning at the tendinotic site. The impression of the radiologist is that the area of Achilles hypertrophic tendinopathy decreased in thickness with declining (normalizing) signal intensity on T1 and STIR. The RSI used to describe the significant tendinotic area changes represent a turning back of the destructive process in the tendon, decreasing from 307.839 to 182.471. This type of improvement is not seen even with reconstruction, after which the scar tissue still appears echogenic on MRI.

At this point, the patient is doing much better clinically, with decreased VAS scores, tolerating high levels of physical court sports and returning to normal daily activities. With this report, we highlight the therapeutic use of BMAC to heal Achilles tendinopathy in a physically active adult. More studies are needed to confirm the therapeutic benefits of this procedure, including the regenerative healing, but we suggest it could represent a viable and more effective alternative than current treatments for Achilles tendinopathy, with actual healing of the affected tendon.

The authors would like to thank Ms. Dorita Avila for her help with preparing this manuscript.

**Conflict of Interests**

RWM and NHR are both shareholders and consultants to Biologic Therapies, Inc, Ocala, FL, USA.
Figure 1  MRI of the patient’s left ankle prior to intervention, performed on a Hitachi 0.3 Tesla device. The name of the patient has been blacked out. Special thanks to Dr. Paul Marsh, D.O. of Monticello Diagnostic Imaging for compiling these images.
A. Sagittal T1 left ankle
B. STIR Sagittal left ankle
C. Sagittal T1 fused with a sagittal STIR left ankle
D. Axial T1 left ankle
E. Axial T2 Fast Spin Echo left ankle
F. Axial T1 zoomed to better show the image measurement of signal intensity and area of involved tissue left ankle
G. Scout view – center green line represents the image slice in F taken at the most involved portion of the tendon left ankle.
Figure 2  MRI of the patient’s left ankle post-operatively, performed on a Hitachi 0.3 Tesla device. The name of the patient has been blacked out. T1 images used for calculations were both performed with a TE of 20, and a TR of 820, utilizing 5.5 mm slice thicknesses. Color fusion with OsiriX Imaging Software.

A. Sagittal T1 left ankle
B. STIR Sagittal left ankle
C. Sagittal T1 fused with a sagittal STIR left ankle
D. Axial T1 left ankle
E. Axial T2 Fast Spin Echo left ankle
F. Axial T1 zoomed to better show the image measurement of signal intensity and area of involved tissue left ankle
G. Scout view – center green line represents the image slice in F taken at the most involved portion of the tendon—left ankle

Special thanks to Dr. Paul Marsh, D.O. of Monticello Diagnostic Imaging for compiling these images.
In Press: Editor,

In a recent publication in this journal we reported a case of chronically injured Achilles tendon that was successfully treated using autologous bone marrow aspirate concentrate in an office setting.[1]

The pre-treatment MRI showed severe hypertrophic changes of the Achilles with marked tendinopathy and a consistent intermediate T1 signal throughout the thick, echogenic area (Figure 1). The cross section of the most hypertrophic area of the tendon measured $2.272\text{-cm}^2$. The hypertrophy extended from about a centimeter above the superior reflection over a distance of about 6-cm, and measured about 2-cm coronally and 1.5-cm from A to P. The relative signal intensity (RSI) was 307.839.

A 10-week post-treatment MRI showed the Achilles had significantly healed by a decrease in the area measured on cross section (from $2.272\text{-cm}^2$ to $1.877\text{-cm}^2$) and a decrease in the Relative Strength Intensity (RSI) from 307.839 to 182.471. (Figure 2)

We wish to update that report with the results of a 32-week post-treatment MRI that was performed using the same scanner as the pre- and 10-week post-treatment MRIs. These images showed near complete healing of the treated tendon. The area on cross section decreased from 2.272 to 1.204 and the Relative Strength Intensity RSI decreased from 307.839 to 90.356. Unaffected tendon on the same MRI showed a mean RSI of 72.536 (Figure 4). Figure 3 shows the progression of the RSI from pretreatment to the 32-week post-treatment MRI.


Figure 3
Figure 4. MRI of the patient’s left ankle post-operatively, performed on a Hitachi 0.3 Tesla device. The name of the patient has been blacked out. T1 images used for calculations were both performed with a TE of 20, and a TR of 820, utilizing 5.5-mm slice thicknesses. Color fusion with OsirX Imaging Software.
BOX 1. DESCRIPTION OF THE MAGELLAN AUTOLOGOUS PLATELET SEPARATOR® SYSTEM.

The Bio-Spin Magellan® System consists of the bench top Bio-Spin Magellan® Unit and associated disposables optimized for centrifugal fractionation of peripheral blood and bone marrow. High precision optical sensors identify the target therapeutic cellular rich-fraction, which the System has separated from the red blood fraction, and captures it (along with a small volume of the plasma fraction). Separation is performed in an automated, closed-loop, sterile disposable unit easily loaded onto the Magellan® Unit.

In approximately 15 minutes, the Bio-Spin Magellan System utilizes two spin cycles to separate out the therapeutic fraction from unwanted cells. The first cycle (2800 rpm) allow for the heavier cells, such as red blood cells and granulocytes to concentrate prior to being withdrawn from the sterile disposable into a waste syringe. Thereafter, the system enters into a second harder spin (3800 rpm) which concentrates a “buffy coat” of platelets and nucleated cells, which is automatically collected into an excipient syringe to be used by the physician. The Bio-Spin Magellan System allows for the user to select a desired output volume, 3 to 10 mL, to be collected. After the separation chamber is installed, and the two syringes are locked into the pumps on the front of the instrument, the separation process is completely automated.

Table 1

TABLE 1. SCORES OF THE VISUAL ANALOG SCALE (VAS) FOR PAIN AT REST, ON WALKING AND AT TOE-RAISING AND DORSIFLEXION BEFORE AND AFTER THE INTERVENTION.

<table>
<thead>
<tr>
<th></th>
<th>Pre intervention</th>
<th>Post intervention (8 weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td>At rest</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Walking</td>
<td>9</td>
<td>2</td>
</tr>
</tbody>
</table>
References

26. Ryan M, Wong A, Taunton J. Favorable outcomes after sonographically guided intratendinous injection of